Ashwani Verma
Stock Analyst at UBS
(3.92)
# 773
Out of 5,182 analysts
109
Total ratings
54.55%
Success rate
9.64%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Buy | $251 → $259 | $178.11 | +45.42% | 8 | Apr 10, 2026 | |
| INCY Incyte | Maintains: Neutral | $104 → $94 | $96.07 | -2.15% | 3 | Mar 25, 2026 | |
| ALVO Alvotech | Maintains: Buy | $10 → $6 | $3.62 | +65.75% | 2 | Mar 24, 2026 | |
| CYTK Cytokinetics | Maintains: Neutral | $61 → $69 | $65.01 | +6.14% | 6 | Mar 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $655 → $705 | $571.73 | +23.31% | 12 | Mar 5, 2026 | |
| HRMY Harmony Biosciences Holdings | Downgrades: Neutral | $43 → $46 | $28.89 | +59.22% | 4 | Feb 11, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $178 | $128.89 | +38.10% | 11 | Jan 23, 2026 | |
| INSM Insmed | Maintains: Buy | $223 → $215 | $154.81 | +38.88% | 1 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $21.74 | +83.99% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $41.91 | +126.68% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $48 | $18.16 | +164.32% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $26 → $11 | $9.17 | +19.96% | 5 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $163 → $188 | $194.20 | -3.19% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $207.94 | +5.80% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $44.27 | -9.65% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $30.82 | -15.64% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $24.50 | -26.53% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $33.36 | +25.90% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.68 | -37.50% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $114.83 | -0.72% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $47.90 | -41.54% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $307.50 | -97.72% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $13.47 | -10.91% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.74 | +1,927.03% | 1 | Oct 11, 2022 |
Axsome Therapeutics
Apr 10, 2026
Maintains: Buy
Price Target: $251 → $259
Current: $178.11
Upside: +45.42%
Incyte
Mar 25, 2026
Maintains: Neutral
Price Target: $104 → $94
Current: $96.07
Upside: -2.15%
Alvotech
Mar 24, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.62
Upside: +65.75%
Cytokinetics
Mar 6, 2026
Maintains: Neutral
Price Target: $61 → $69
Current: $65.01
Upside: +6.14%
United Therapeutics
Mar 5, 2026
Maintains: Buy
Price Target: $655 → $705
Current: $571.73
Upside: +23.31%
Harmony Biosciences Holdings
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $28.89
Upside: +59.22%
Neurocrine Biosciences
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $128.89
Upside: +38.10%
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $154.81
Upside: +38.88%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $21.74
Upside: +83.99%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $41.91
Upside: +126.68%
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $18.16
Upside: +164.32%
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $9.17
Upside: +19.96%
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $194.20
Upside: -3.19%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $207.94
Upside: +5.80%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $44.27
Upside: -9.65%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $30.82
Upside: -15.64%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $24.50
Upside: -26.53%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $33.36
Upside: +25.90%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.68
Upside: -37.50%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $114.83
Upside: -0.72%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $47.90
Upside: -41.54%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $307.50
Upside: -97.72%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $13.47
Upside: -10.91%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.74
Upside: +1,927.03%